一种口服有效的促甲状腺激素受体配体抑制甲状腺癌的生长和转移活性
本研究从超过200种促甲状腺激素受体(TSHR)配体中筛选出A35,在体外和免疫功能低下小鼠的甲状腺癌(TC)细胞源性异种移植模型中评估其抗增殖和抗转移活性。A35在部分细胞类型中激活TSHR刺激cAMP生成,但在TC细胞MDA-T32和MDA-T85中无此作用;A35抑制MDA-T32和MDA-T85的体外和体内增殖,并抑制MDA-T85F1小鼠肺转移;A35抑制CDX肿瘤生长且小鼠体重和肝功能未下降,肿瘤Ki67和肺组织转移标志物降低。作者认为A35是TSHR选择性TC细胞增殖和转移抑制剂,可能是治疗人分化型TC的有前景的先导药物候选。
要点
- A35在TC细胞MDA-T32和MDA-T85中不刺激cAMP生成,但抑制其体外和体内增殖。
- A35抑制MDA-T85F1小鼠肺转移,并降低肿瘤Ki67和肺组织转移标志物水平。
- A35抑制CDX肿瘤生长且小鼠体重和肝功能未下降,作者认为其可能是治疗人分化型TC的先导药物候选。
核心结论
- 作者结论为A35是TSHR选择性TC细胞增殖和转移抑制剂,并建议A35可能是治疗人分化型TC的有前景的先导药物候选。
研究设计与样本
- 从超过200种TSHR配体亚库中筛选出A35(NCATS-SM4420;NCGC00241808)。
- 进行包括BrdU掺入和WST-1的细胞增殖实验以及分子对接研究。
- 在免疫功能低下(NSG)小鼠的TC细胞源性异种移植(CDX)模型中评估A35的体内活性。
- 观察肿瘤和肺组织福尔马林固定石蜡包埋切片的细胞死亡和转移程度。
主要发现
- A35在部分细胞类型中通过激活TSHR刺激cAMP生成,但在TC细胞MDA-T32和MDA-T85中不刺激cAMP生成。
- A35抑制MDA-T32和MDA-T85的体外和体内增殖,并抑制MDA-T85F1小鼠的肺转移。
- 体外实验中,选择性TSHR拮抗剂减弱A35对增殖的抑制作用。
- A35抑制CDX肿瘤生长且小鼠体重和肝功能未下降,显示有效且无明显毒性。
- A35降低肿瘤中Ki67水平和肺组织中转移标志物水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid-stimulating hormone (or thyrotropin) receptor (TSHR) could be a selective target for small molecule ligands to treat thyroid cancer (TC). OBJECTIVE: We report a novel, orally efficacious ligand for TSHR that exhibits proliferation inhibitory activity against human TC in vitro and in vivo, and inhibition of metastasis in vivo. METHODS: A35 (NCATS-SM4420; NCGC00241808) was selected from a sublibrary of >200 TSHR ligands. Cell proliferation assays including BrdU incorporation and WST-1, along with molecular docking studies were done. In vivo activity of A35 was assessed in TC cell-derived xenograft (CDX) models with immunocompromised (NSG) mice. Formalin-fixed, paraffin-embedded sections of tumor and lung tissues were observed for the extent of cell death and metastasis. RESULTS: A35 was shown to stimulate cAMP production in some cell types by activating TSHR but not in TC cells, MDA-T32, and MDA-T85. A35 inhibited proliferation of MDA-T32 and MDA-T85 in vitro and in vivo, and pulmonary metastasis of MDA-T85F1 in mice. In vitro, A35 inhibition of proliferation was reduced by a selective TSHR antagonist. Inhibition of CDX tumor growth without decreases in mouse weights and liver function showed A35 to be efficacious without apparent toxicity. Lastly, A35 reduced levels of Ki67 in the tumors and metastatic markers in lung tissues. CONCLUSION: We conclude that A35 is a TSHR-selective inhibitor of TC cell proliferation and metastasis, and suggest that A35 may be a promising lead drug candidate for the treatment of differentiated TC in humans.
引用
- Sarkar R, Bolel P, Kapoor A, et al. An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers. J Clin Endocrinol Metab. 2024. PMID: 38421044. doi:10.1210/clinem/dgae114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。